Johnson Matthey Catalysis & Chiral Technologi?es Announces Commercial?-Scale Tethered Catalyst Offer
![](/46/pdcnewsitem/03/29/66/SZjovdxNOBMHZXh.png)
Johnson Matthey Catalysis and Chiral Technologies (JMCCT), a business unit of Johnson Matthey Fine Chemical Division, has expanded its proprietary tethered catalyst technology, and is now offering multi-kilogram quantities for application in commercial processes. The migration to commercial-scale quantities was a direct response to customer demand for active, stable and flexible catalysts for use in asymmetric transfer hydrogenation reactions.
The technology, originally developed by Professor Martin Wills at the University of Warwick, has been successfully launched working in close collaboration with customers to develop new API manufacturing applications. In 2013, JMCCT began work to expand the availability of the current two variants of tethered catalyst to multi-kilograms scale. The tethered catalyst offer is now available for use in both hydrogenation and transfer hydrogenation, and has shown exceptional results in increasing activity and robustness against polyfunctionalized substrates.
Plans to expand the current product line are underway, supported by the U.K. government’s Technology Strategy Board’s recent grant funding of a joint research program between JMCCT and the University of Warwick for the development of phosphine-free hydrogenation catalysts.
“The availability at commercial scale of the tethered catalyst technology is the demonstration of our continuous commitment to the advancement of chiral chemocatalysis,” noted Daren Bryce, Commercial Manager at JMCCT. “We believe the successful collaboration with Warwick University and the launch of further tethered catalysts throughout 2014 makes the JMCCT offer the most active, stable and flexible catalytic technology on the market.”
Ruthenium(II) catalysts for asymmetric transfer hydrogenation reactions are often referred to as tethered catalysts because the chiral and arene ligand components are covalently linked, helping the chiral component to remain in the correct conformation, and preventing the arene component from rotating. This gives higher activity and stability to the transfer hydrogenation catalyst, making its performance much more similar to pressure hydrogenation catalysts, but without the need of specialized manufacturing equipment. In particular, JMCCT tethered catalysts have proven applicable to traditionally difficult substrates such as alpha-chloroacetophenone, propargyl ketones and polyfunctionalized molecules, and also shown excellent results in other client applications.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance